Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Korro Bio ( (KRRO) ) has provided an update.
At the 2025 annual meeting held on June 11, Korro Bio‘s stockholders elected Ram Aiyar, Jean-François Formela, and Katharine Knobil as Class III directors for a three-year term ending in 2028. Additionally, stockholders approved the compensation of Korro’s named executive officers and decided on a ‘1 Year’ frequency for future advisory votes on this matter. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (KRRO) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
Korro Bio’s stock score reflects its current position as a developmental biotech firm. Financial performance is the most significant factor, showing the challenges of high R&D costs and reliance on external funding. The technical analysis suggests short-term downward pressure, while valuation is impacted by its negative earnings and lack of dividends. The company needs to focus on operational efficiency and revenue growth to improve its stock performance.
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Average Trading Volume: 139,514
Technical Sentiment Signal: Sell
Current Market Cap: $148.8M
See more data about KRRO stock on TipRanks’ Stock Analysis page.